Daiichi Sankyo Co Ltd News - D4S

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotama ...

TOP NEWS: Daiichi forecasts further revenue growth after strong year

Daiichi Sankyo Co Ltd on Wednesday said that strong sales of its flagship medicines drove revenue growth in its lates ...

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved t ...

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

escription of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria) (Alliance News ...

AstraZeneca and Daiichi make US progress with latest licence approvals

AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US. The Cambri ...

AstraZeneca's breast cancer treatment blocked for NHS use in England

A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a ...

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketin ...

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc. The Cambridge-based pharmaceutical ...

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

AstraZeneca PLC on Monday announced new study data and a new approval for its cancer medication Tagrisso. The Cambr ...

Daiichi Sankyo ups full-year guidance, as weak yen boosts third quarter

Daiichi Sankyo Co Ltd on Wednesday said it was raising annual guidance after seeing solid growth in the first nine mo ...

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration i ...

Daiichi Sankyo ups revenue and profit, boosts quarterly dividend

Daiichi Sankyo Co Ltd on Tuesday said revenue in its first half year was up by 20% and increased its second quarterly ...

AstraZeneca celebrates drug trial results for cancer indications

AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive result ...

TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal

Shares in Japan's Daiichi Sankyo Co Ltd soared on Friday after the pharma group announced a major cancer drug deal w ...

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday. Daiichi i ...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Daiichi Sankyo Co Ltd (D4S)

Empower your portfolio: Real-time discussions and actionable trading ideas.

D4S News

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

TOP NEWS: Daiichi forecasts further revenue growth after strong year

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

AstraZeneca and Daiichi make US progress with latest licence approvals

AstraZeneca's breast cancer treatment blocked for NHS use in England

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

Daiichi Sankyo ups full-year guidance, as weak yen boosts third quarter

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

Daiichi Sankyo ups revenue and profit, boosts quarterly dividend

AstraZeneca celebrates drug trial results for cancer indications

TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

D4S Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Daiichi Sankyo Co Ltd (D4S) News

Daiichi Sankyo Co Ltd (D4S)

Empower your portfolio: Real-time discussions and actionable trading ideas.

D4S News

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

TOP NEWS: Daiichi forecasts further revenue growth after strong year

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

AstraZeneca and Daiichi make US progress with latest licence approvals

AstraZeneca's breast cancer treatment blocked for NHS use in England

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

TOP NEWS: AstraZeneca celebrates Tagrisso approval and new data

Daiichi Sankyo ups full-year guidance, as weak yen boosts third quarter

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

Daiichi Sankyo ups revenue and profit, boosts quarterly dividend

AstraZeneca celebrates drug trial results for cancer indications

TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

D4S Discussion

Your Recent History